Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Navidea Biopharmaceuticals
Neoprobe butts heads with Lymphoseek critics
Neoprobe Corp. (NYSE:NEOP) responded to a citizen petition sent to the U.S. Food & Drug Administration today, defending clinical trials of its Lymphoseek radiopharmaceutical.
MSMB Capital Management submitted the petition asking the FDA to block Neoprobe’s application on the grounds that the drug’s pivotal trials suffered from vital mistakes.
Among the allegations are that the trials were not adequately controlled and contained conflicts of interest that may have compromised the integrity of the findings.
Histogenics CEO denies Israeli report of R&D layoffs | Personnel Moves
Histogenics Corp., fresh from a merger with fellow Bay State firm Prochon Biotech, has no plans for layoffs, contrary to a report in an Israeli journal.
The Globes new outlet, a business daily based in Rishon Le-Zion, Israel, reported yesterday that Histogenics "will make substantial cuts" to its R&D unit in Ness Ziona.
Neoprobe sells radiation detection sector to Devicor | Acquisitions roundup
Cancer diagnostics firm Neoprobe Corp. (NYSE:NEOP) sold its Gamma Detection Systems sector to Devicor Medical Products Inc. in a deal that’s worth up to $50 million.
Devicor, based in Pleasant Valley, Wis., agreed to pay $30 million up front and up to $20 million in royalty payments.
Dublin, Ohio-based Neoprobe will get the full royalty payment if Devicor tops $21 million in sales of the devices in the next five years.
Neoprobe deflects concerns over clinical trial
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) shot back at critics of the company’s latest phase 3 clinical trial of its radiopharmaceutical Lymphoseek.
“It’s clear this was the right study done the right way,” CEO Mark Pykett said during a conference call with investors and analysts to discuss the company’s first-quarter financial results.
AtriCure aims for FDA approval with “hybrid” atrial fibrillation trial
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure Inc.’s (NSDQ:ATRC) U.S. business, the company’s CEO said.
The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is called DEEP AF, will involve expanding studies from six research centers to 35, CEO David Drachman said.
Neoprobe readies $100 million public offering
Cancer diagnostics firm Neoprobe Corp. (NYSE Amex:NEOP) filed a regulatory document that gives it the right to sell up to $100 million in shares.
However, the Dublin, Ohio-based company has no immediate plans to issue those new shares, CFO Brent Larson said.
“This is just good corporate governance,” Larson said. “There are no plans to sell these shares as of now.”
Neoprobe dodges proxy fight with largest shareholder
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) avoided a proxy fight with its largest shareholder reaching an agreement on board nominations.
The shareholder, Platinum Montaur Life Sciences, last month threatened Neoprobe with a proxy fight aimed at installing three new directors on the Dublin, Ohio-based company’s board.
Bupp steps down as Neoprobe CEO | Personnel moves
Neoprobe Corp. (NYSE Amex:NEOP) is getting a new chief executive and, perhaps, a new board member.
The Dublin, Ohio-based cancer diagnostics firm announced that CEO David Bupp will be replaced by chief development officer Mark Pykett on April 15.
Cancer diagnostics: With proxy fight looming, can Neoprobe deliver the goods?
As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) prepares for a potential proxy fight with Platinum-Montaur Life Sciences, the company’s largest investor, it’s worth taking a look at the Dublin, Ohio-based company’s exit potential.
Neoprobe’s largest backer gears up for proxy war
Neoprobe Corp.’s (NYSE:NEOP) largest shareholder said it’s considering launching a proxy fight aimed at installing three new directors on the cancer diagnostics company’s board.